Gretchen E Glaser1, Eleftheria Kalogera2, Amanika Kumar2, Johnny Yi3, Christopher Destephano4, Daniel Ubl5, Amy Glasgow5, Elizabeth Habermann5, Sean C Dowdy2. 1. Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. Electronic address: glaser.gretchen@mayo.edu. 2. Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, 200 1st St. SW, Rochester, MN 55905, USA. 3. Division of Gynecologic Surgery, Department of Gynecology, Mayo Clinic, 5777 E. Mayo Blvd., Phoenix, AZ 85054, USA. 4. Division of Medical and Surgical Gynecology, Department of Obstetrics and Gynecology, Mayo Clinic, 4500 San Pablo Rd., Jacksonville, FL 32224, USA. 5. Robert D. and Patricia E. Kern Center for the Science of Healthcare Delivery, Mayo Clinic, 200 First St. SW, Rochester, MN 55905, USA.
Abstract
OBJECTIVES: To report the impact of implementing standardized guidelines for opioid prescriptions after gynecologic surgery and describe patient perspectives before and after implementation for those undergoing laparotomy for ovarian cancer. METHODS: Patients undergoing gynecologic surgery between October 2017 and May 2018 were prescribed opioids at discharge using tiered guidelines; prescriptions were compared to consecutive historical controls (March 2017-October 2017). A subset of ovarian cancer laparotomy patients were surveyed regarding postoperative opioid consumption and patient experience. RESULTS: A total of 620 women in the tiered guideline cohort were compared with 599 historical controls. Following implementation, 95.8% of prescriptions met guidelines. Median milligram morphine equivalents (MME) prescribed decreased from 150 to 75 (p ≤ 0.001) with no change in opioid refills (7.7 vs 6.9%, p = 0.62). In surveyed ovarian cancer patients, 100% of tiered guideline patients and 92% of historical controls felt satisfied with pain control (p = 0.24), despite a 50% reduction in prescribed MME and 14.6% receiving no opioids at discharge (p = 0.002). The median (IQR) MME consumed after discharge was 15 (0, 75) in tiered guideline patients vs. 24 (0, 135) in historical controls, and 38.2% and 42.4% consumed no opioids, respectively. Mean time between surgery and opioid use cessation was <1 week in both groups; patients' perceptions of opioid prescription appropriateness did not change (p = 0.49). More than 75% of patients kept their remaining opioids rather than dispose of them. CONCLUSIONS: Reducing prescribed opioids after gynecologic surgery using tiered guidelines did not increase opioid refills or worsen patients' perceptions of postoperative pain. Even after laparotomy, very little opioids were required over a short duration after dismissal. Infrequent disposal of leftover opioids highlights the need to avoid over-prescribing.
OBJECTIVES: To report the impact of implementing standardized guidelines for opioid prescriptions after gynecologic surgery and describe patient perspectives before and after implementation for those undergoing laparotomy for ovarian cancer. METHODS:Patients undergoing gynecologic surgery between October 2017 and May 2018 were prescribed opioids at discharge using tiered guidelines; prescriptions were compared to consecutive historical controls (March 2017-October 2017). A subset of ovarian cancer laparotomypatients were surveyed regarding postoperative opioid consumption and patient experience. RESULTS: A total of 620 women in the tiered guideline cohort were compared with 599 historical controls. Following implementation, 95.8% of prescriptions met guidelines. Median milligram morphine equivalents (MME) prescribed decreased from 150 to 75 (p ≤ 0.001) with no change in opioid refills (7.7 vs 6.9%, p = 0.62). In surveyed ovarian cancerpatients, 100% of tiered guideline patients and 92% of historical controls felt satisfied with pain control (p = 0.24), despite a 50% reduction in prescribed MME and 14.6% receiving no opioids at discharge (p = 0.002). The median (IQR) MME consumed after discharge was 15 (0, 75) in tiered guideline patients vs. 24 (0, 135) in historical controls, and 38.2% and 42.4% consumed no opioids, respectively. Mean time between surgery and opioid use cessation was <1 week in both groups; patients' perceptions of opioid prescription appropriateness did not change (p = 0.49). More than 75% of patients kept their remaining opioids rather than dispose of them. CONCLUSIONS: Reducing prescribed opioids after gynecologic surgery using tiered guidelines did not increase opioid refills or worsen patients' perceptions of postoperative pain. Even after laparotomy, very little opioids were required over a short duration after dismissal. Infrequent disposal of leftover opioids highlights the need to avoid over-prescribing.
Authors: Allison Kirkegaard; Zachary Wagner; Louis T Mariano; Meghan C Martinez; Xiaowei Sherry Yan; Robert J Romanelli; Katherine E Watkins Journal: BMJ Open Date: 2022-09-19 Impact factor: 3.006
Authors: R Tyler Hillman; Maria D Iniesta; Qiuling Shi; Tina Suki; Tsun Chen; Katherine Cain; Loretta Williams; Xin Shelley Wang; Jolyn S Taylor; Gabriel Mena; Javier Lasala; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2020-11-06 Impact factor: 3.437
Authors: Sarah Huepenbecker; Robert Tyler Hillman; Maria D Iniesta; Tsun Chen; Katherine Cain; Gabriel Mena; Javier Lasala; Xin Shelley Wang; Loretta Williams; Jolyn S Taylor; Karen H Lu; Pedro T Ramirez; Larissa A Meyer Journal: Int J Gynecol Cancer Date: 2021-06-16 Impact factor: 4.661